Six randomized studies have now been reported that demonstrate the superiority of either gefitinib or erlotinib over chemotherapy in NSCLC patients with EGFR mutations [12,13,14,15,16,17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.